<DOC>
	<DOC>NCT00104338</DOC>
	<brief_summary>The purpose of this study is to assess the safety and effectiveness of a new oral immunosuppressant agent compared to standard care in renal transplant patients diagnosed with BK nephropathy.</brief_summary>
	<brief_title>Study of FK778 in Renal Transplant Recipients With Untreated BK Nephropathy</brief_title>
	<detailed_description>The purpose of this study is to assess the efficacy and safety of FK778 compared with standard care in renal transplant recipients with newly diagnosed and untreated BK nephropathy.</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<criteria>Renal transplant recipient with newly diagnosed BK nephropathy. Previous treatment for BK nephropathy Organ transplant other than kidney Uncontrolled concomitant infection other than BK nephropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Investigational Therapies</keyword>
	<keyword>Treatment Effectiveness</keyword>
	<keyword>Treatment Efficacy</keyword>
	<keyword>Immunosuppressant</keyword>
	<keyword>BK Nephropathy</keyword>
	<keyword>Polyomavirus, BK</keyword>
	<keyword>Human Polyomavirus BK</keyword>
	<keyword>Polyomavirus hominis 1</keyword>
</DOC>